Therapeutic window for melanoma treatment provided by selective effects of the proteasome on Bcl-2 proteins
Open Access
- 1 June 2007
- journal article
- research article
- Published by Springer Nature in Cell Death & Differentiation
- Vol. 14 (9) , 1605-1616
Abstract
Melanoma cells depend on sustained proteasomal function for survival. However, bortezomib, the first proteasome inhibitor in clinical use, is not sufficient to improve the poor prognosis of metastatic melanoma patients. Since the proteasome is also expressed in all normal cell compartments, it is unclear how to enhance the efficacy of bortezomib without exacerbating secondary toxicities. Here, we present pharmacological and genetic analyses of mechanisms of resistance to proteasome inhibition. We focused on Bcl-2, Bcl-xL and Mcl-1 as main antiapoptotic factors associated with melanoma progression. Despite an efficient blockage of the proteasome, bortezomib could not counteract the intrinsically high levels of Bcl-2 and Bcl-xL in melanoma cells. Moreover, Mcl-1 was only downregulated at late time points after treatment. Based on these results, a combination treatment including (−)-gossypol, an inhibitor of Mcl-1/Bcl-2/Bcl-xL, was designed and proven effective in vivo. Using a specific RNA interference approach, the survival of bortezomib-treated melanoma cells was found to rely primarily on Mcl-1, and to a lesser extent on Bcl-xL (but not on Bcl-2). Importantly, neither Mcl-1 nor Bcl-xL inactivation affected the viability of normal melanocytes. This hierarchical requirement of Bcl-2 family members for the maintenance of normal and malignant cells offers a therapeutic window to overcome melanoma chemoresistance in a tumor cell-selective manner.Keywords
This publication has 36 references indexed in Scilit:
- Ultraviolet radiation triggers apoptosis of fibroblasts and skin keratinocytes mainly via the BH3-only protein NoxaJournal of Cell Biology, 2007
- Enhanced Killing of Melanoma Cells by Simultaneously Targeting Mcl-1 and NOXACancer Research, 2006
- Proteasome Inhibitor PS-341 Induces Apoptosis in Cisplatin-resistant Squamous Cell Carcinoma Cells by Induction of NoxaJournal of Biological Chemistry, 2006
- Malignant melanoma: genetics and therapeutics in the genomic eraGenes & Development, 2006
- The proteasome inhibitor bortezomib induces apoptosis in mantle-cell lymphoma through generation of ROS and Noxa activation independent of p53 statusBlood, 2006
- Differential Regulation of Noxa in Normal Melanocytes and Melanoma Cells by Proteasome Inhibition: Therapeutic ImplicationsCancer Research, 2005
- Proteasome Inhibitors Trigger NOXA-Mediated Apoptosis in Melanoma and Myeloma CellsCancer Research, 2005
- Differential Targeting of Prosurvival Bcl-2 Proteins by Their BH3-Only Ligands Allows Complementary Apoptotic FunctionMolecular Cell, 2005
- Augmenting Chemosensitivity of Malignant Melanoma Tumors via Proteasome InhibitionCancer Research, 2004
- Apoptosis and melanoma chemoresistanceOncogene, 2003